Nowadays, atezolizumab plus bevacizumab is recommended for advanced hepatocellular carcinoma (HCC) as the first-line systemic chemotherapy. Nevertheless, the data with regard to the tumor response still remain limited. We report a complete metabolic response assessed by 18 F-FDG PET/CT in a 74-year-old man with advanced HCC who underwent atezolizumab plus bevacizumab followed by radical hepatectomy. Furthermore, pathological examination revealed that the tumor showed complete response for this therapy. This case suggests that 18 F-FDG PET/CT represents clinical relevance as a useful approach for therapeutic assessment of immune-oncology drugs in HCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000004570 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: To evaluate the safety, diagnostic accuracy, and factors influencing the diagnostic yield of ultrasound (US)-guided omental biopsies.
Materials And Methods: This retrospective study included 109 patients who underwent US-guided omental biopsies between June 2020 and June 2024. Pre-biopsy diagnostic images (CT, MRI, or [18 F]FDG PET/CT) were reviewed.
Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma.
Biomolecules
December 2024
Department of Translational Medicine, University of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy.
Prostate cancer (PCa) is a high-prevalence disease usually characterized by metastatic spread to the pelvic lymph nodes and bones and the development of visceral metastases only in the late stages of disease. Positron Emission Tomography (PET) plays a key role in the detection of PCa metastases. Several PET radiotracers are used in PCa patients according to the stage and pathological features of the disease, in particular Ga/F-prostate-specific membrane antigen (PSMA) ligands.
View Article and Find Full Text PDFNuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions.
Cancers (Basel)
January 2025
Urology Department, South Metropolitan Health Service, Murdoch, WA, 6150, Australia.
: The role of molecular imaging in urothelial cancer is less defined than other cancers, and its utility remains controversial due to limitations such as high urinary tracer excretion, complicating primary tumour assessment in the bladder and upper urinary tract. This review explores the current landscape of PET imaging in the clinical management of urothelial cancer, with a special emphasis on potential future advancements including emerging novel non-F FDG PET agents, PET radiopharmaceuticals, and PET-MRI applications. : We conducted a comprehensive literature search in the PubMed database, using keywords such as "PET", "PET-CT", "PET-MRI", "FDG PET", "Urothelial Cancer", and "Theranostics".
View Article and Find Full Text PDFThe Role of [F]FDG PET and Clinicopathologic Factors in Detecting and Predicting Bone Marrow Involvement in Non-Hodgkin Lymphoma.
Cancers (Basel)
January 2025
Department of Pathology, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.
: This study evaluates the diagnostic accuracy of [18F]fluorodeoxyglucose ([F]FDG) positron emission tomography (PET) using bone marrow biopsy (BMB) and clinical follow-up as reference standards. It further identifies predictive factors for bone marrow involvement (BMI) in non-Hodgkin lymphoma (NHL) patients. : NHL patients who underwent [F]FDG PET and BMB at diagnosis in a tertiary cancer center were included in this study.
View Article and Find Full Text PDFSuccessful Pregnancy Outcome in a Patient Treated with Pembrolizumab and Exposed to Fluoro-Deoxyglucose (F-FDG) PET/CT: Case Report and Review of Literature.
Biomedicines
January 2025
Department of Obstetrics and Gynecology, Center of Maternal Fetal Medicine, Universitary Hospital, University of Foggia, 71122 Foggia, Italy.
Hodgkin lymphoma (HL) is a common malignancy among women of reproductive age. Some pregnancies occur during oncological treatments or diagnostic follow-ups, often involving contraindicated procedures. HL is fluorodeoxyglucose-avid; therefore, its staging is generally performed with F-FDG PET/CT, a diagnostic method contraindicated during pregnancy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!